[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Alogliptin.]
[B01AD01, streptokinase, The risk or severity of angioedema can be increased when Streptokinase is combined with Alogliptin.]
[J01GA01, streptomycin, Alogliptin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01CG01, sulbactam, Alogliptin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Alogliptin.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Alogliptin.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Alogliptin.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BB04, glibornuride, Alogliptin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Glymidine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Alogliptin.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Alogliptin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Alogliptin.]
[N07XX06, tetrabenazine, The metabolism of Alogliptin can be decreased when combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Alogliptin can be decreased when combined with Dronabinol.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Alogliptin.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AC02, thioridazine, The metabolism of Alogliptin can be decreased when combined with Thioridazine.]
[C01BB04, aprindine, The metabolism of Alogliptin can be decreased when combined with Aprindine.]
[G04BE06, moxisylyte, Alogliptin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Alogliptin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Alogliptin can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01AA12, tobramycin, Alogliptin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Alogliptin may increase the hypoglycemic activities of Tolazamide.]
[V04CA01, tolbutamide, Alogliptin may increase the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Alogliptin can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The metabolism of Alogliptin can be decreased when combined with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Alogliptin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Alogliptin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Alogliptin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Alogliptin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Alogliptin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Alogliptin.]
[A03AA05, trimebutine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Alogliptin.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Alogliptin.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Alogliptin.]
[R06AC04, tripelennamine, The metabolism of Alogliptin can be decreased when combined with Tripelennamine.]
[J01FA08, troleandomycin, The metabolism of Alogliptin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Alogliptin can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of angioedema can be increased when Alogliptin is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R02AA14, oxyquinoline, Alogliptin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Alogliptin can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Alogliptin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Alogliptin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Alogliptin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Alogliptin can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of angioedema can be increased when Urokinase is combined with Alogliptin.]
[S01AA28, vancomycin, Alogliptin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AF01, rivaroxaban, Alogliptin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The metabolism of Alogliptin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Alogliptin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Alogliptin can be decreased when combined with Vinblastine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AA03, warfarin, Alogliptin may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Xipamide.]
[N05AF05, zuclopenthixol, The metabolism of Alogliptin can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Alogliptin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Alogliptin can be increased when used in combination with Vemurafenib.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B06AC02, icatibant, The risk or severity of angioedema can be increased when Icatibant is combined with Alogliptin.]
[L01ED01, crizotinib, The metabolism of Alogliptin can be decreased when combined with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Alogliptin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Alogliptin.]
[L01EJ01, ruxolitinib, Alogliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DH04, doripenem, Alogliptin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Alogliptin can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Alogliptin.]
[B03XA04, peginesatide, Alogliptin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Alogliptin.]
[M03BX01, baclofen, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The metabolism of Alogliptin can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Alogliptin can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Alogliptin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Alogliptin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Alogliptin.]
[D02BA02, octinoxate, Alogliptin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Alogliptin can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Alogliptin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Alogliptin.]
[N06DA02, donepezil, The metabolism of Alogliptin can be decreased when combined with Donepezil.]
[G04BD10, darifenacin, The metabolism of Alogliptin can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Alogliptin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Alogliptin can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Alogliptin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Alogliptin.]
[A16AX08, teduglutide, Alogliptin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Alogliptin.]
[S01AA13, fusidic acid, The metabolism of Alogliptin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Alogliptin can be increased when used in combination with Pipemidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Alogliptin can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, Alogliptin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Alogliptin can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Alogliptin.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Alogliptin can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Alogliptin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Alogliptin can be decreased when combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Alogliptin.]
[L03AA12, ancestim, Alogliptin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Alogliptin can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01EE01, trametinib, Alogliptin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Alogliptin.]
[V09AX05, florbetapir F-18, Alogliptin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Alogliptin.]
[C08EA02, bepridil, The metabolism of Alogliptin can be decreased when combined with Bepridil.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Lixisenatide.]
[C02KX04, macitentan, Alogliptin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Alogliptin.]
[N06AX26, vortioxetine, Alogliptin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Alogliptin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Alogliptin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Alogliptin.]
[C01CA27, droxidopa, Alogliptin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Alogliptin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[A16AA07, metreleptin, The metabolism of Alogliptin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Alogliptin can be increased when combined with Apremilast.]
[L02BG02, formestane, Alogliptin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Alogliptin.]
[S01ED02, betaxolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Alogliptin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ceritinib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Alogliptin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX10, eliglustat, The metabolism of Alogliptin can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Alogliptin can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Dulaglutide.]
[N04AA02, biperiden, The metabolism of Alogliptin can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Alogliptin can be decreased when combined with Pirfenidone.]
[S03AA06, gentamicin, Alogliptin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Alogliptin.]
[B01AF03, edoxaban, Alogliptin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Alogliptin can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Alogliptin can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Alogliptin can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Alogliptin can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Alogliptin can be decreased when combined with Rolapitant.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Alogliptin.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01EC01, acetazolamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Alogliptin can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Alogliptin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Alogliptin.]
[J02AC05, isavuconazole, The metabolism of Alogliptin can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Alogliptin.]
[L01XG03, ixazomib, Alogliptin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, Alogliptin may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Alogliptin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Alogliptin.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01XX52, venetoclax, The metabolism of Alogliptin can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Alogliptin.]
[A02AD05, aluminum magnesium silicate, Alogliptin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Alogliptin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Alogliptin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Alogliptin.]
[C03CA02, bumetanide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Alogliptin can be decreased when combined with Bupivacaine.]
[C07AA19, bupranolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Alogliptin can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Alogliptin can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Alogliptin can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Alogliptin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Alogliptin.]
[A06AH05, naldemedine, Alogliptin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Alogliptin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Alogliptin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Alogliptin.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Benfluorex.]
[P01CA02, benznidazole, Alogliptin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Alogliptin.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Alogliptin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Alogliptin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Alogliptin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Alogliptin can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Alogliptin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Delafloxacin.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Alogliptin.]
[L01XH01, vorinostat, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Alogliptin can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bopindolol.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Alogliptin.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Alogliptin.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Alogliptin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, Alogliptin may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of angioedema can be increased when Alogliptin is combined with Captopril.]
[L02BB05, apalutamide, The metabolism of Alogliptin can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Alogliptin can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Alogliptin can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, Alogliptin may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Alogliptin.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01GB14, plazomicin, Alogliptin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Alogliptin.]
[L01XX62, ivosidenib, The metabolism of Alogliptin can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Alogliptin.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Alogliptin can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Alogliptin.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BB06, carbutamide, Alogliptin may increase the hypoglycemic activities of Carbutamide.]
[D08AE05, chloroxylenol, Alogliptin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Alogliptin.]
[L04AA39, emapalumab, The metabolism of Alogliptin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A06AX05, prucalopride, Alogliptin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Alogliptin.]
[C09AA08, cilazapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Cilazapril.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[P02BX04, triclabendazole, The metabolism of Alogliptin can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The metabolism of Alogliptin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Alogliptin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, The metabolism of Alogliptin can be decreased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Alogliptin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Alogliptin.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Alogliptin.]
[L04AB01, etanercept, The metabolism of Alogliptin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Alogliptin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Alogliptin can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Alogliptin can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Alogliptin.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Alogliptin can be decreased when combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Alogliptin.]
[G03AC09, desogestrel, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Alogliptin can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Alogliptin can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Alogliptin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB02, dexchlorpheniramine, The metabolism of Alogliptin can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Alogliptin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L04AA53, teprotumumab, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Alogliptin can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Alogliptin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Alogliptin can be decreased when combined with Amprenavir.]
[R02AA03, dichlorobenzyl alcohol, Alogliptin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Alogliptin.]
[N02AA08, dihydrocodeine, The metabolism of Alogliptin can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Alogliptin can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08CA16, clevidipine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Alogliptin.]
[C01BD07, dronedarone, The metabolism of Alogliptin can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Alogliptin.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Alogliptin.]
[G04BD09, trospium, The metabolism of Alogliptin can be decreased when combined with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V08CA05, mangafodipir, Alogliptin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Alogliptin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Alogliptin.]
[P01BB01, proguanil, The metabolism of Alogliptin can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Alogliptin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Alogliptin.]
[P01BA01, chloroquine, The metabolism of Alogliptin can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Alogliptin can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Alogliptin can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Alogliptin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Alogliptin can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Alogliptin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Alogliptin.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B06AC06, berotralstat, The metabolism of Alogliptin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Alogliptin can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Alogliptin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Alogliptin can be increased when it is combined with Abametapir.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MB07, flumequine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Alogliptin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Alogliptin.]
[N02BG07, flupirtine, Alogliptin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Alogliptin can be decreased when combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin human.]
[L03AB10, peginterferon alfa-2b, The metabolism of Alogliptin can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Alogliptin can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Alogliptin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Alogliptin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Ciprofloxacin.]
[L01XA01, cisplatin, Alogliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Alogliptin.]
[H01AC07, somapacitan, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Alogliptin.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lonapegsomatropin.]
[V09AB03, ioflupane I-123, Alogliptin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Alogliptin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Alogliptin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The metabolism of Alogliptin can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BB12, glimepiride, Alogliptin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Alogliptin may increase the hypoglycemic activities of Gliquidone.]
[N06AX25, St. John's wort extract, The metabolism of Alogliptin can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Alogliptin can be decreased when combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Alogliptin.]
[B01AD11, tenecteplase, The risk or severity of angioedema can be increased when Tenecteplase is combined with Alogliptin.]
[B06AX04, mitapivat, The therapeutic efficacy of Alogliptin can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Alogliptin.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Alogliptin.]
[C01EB24, mavacamten, The serum concentration of Alogliptin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Clopamide.]
[A04AA01, ondansetron, The metabolism of Alogliptin can be decreased when combined with Ondansetron.]
[N05AH02, clozapine, The metabolism of Alogliptin can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Sotagliflozin.]
[J01GB12, arbekacin, Alogliptin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Alogliptin.]
[H01AC08, somatrogon, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The metabolism of Alogliptin can be decreased when combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Alogliptin can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R05DA04, codeine, The metabolism of Alogliptin can be decreased when combined with Codeine.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01XB01, colistin, Alogliptin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A04AA03, tropisetron, Alogliptin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Alogliptin.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Alogliptin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Alogliptin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Alogliptin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C05BB03, invert sugar, Alogliptin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V08AB05, iopromide, Alogliptin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Alogliptin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Alogliptin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Alogliptin can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Alogliptin can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Alogliptin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Alogliptin.]
[N03AX09, lamotrigine, Lamotrigine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Alogliptin.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of angioedema can be increased when Alogliptin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Alogliptin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Alogliptin can be decreased when combined with Manidipine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Alogliptin.]
[C07AA14, mepindolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Alogliptin.]
[R06AD07, mequitazine, The metabolism of Alogliptin can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Alogliptin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The metabolism of Alogliptin can be decreased when combined with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Alogliptin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Alogliptin.]
[S01XA18, cyclosporine, The metabolism of Alogliptin can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Alogliptin can be decreased when combined with Moclobemide.]
[C09AA13, moexipril, The risk or severity of angioedema can be increased when Alogliptin is combined with Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Alogliptin can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Alogliptin can be decreased when combined with Danazol.]
[C02CC04, debrisoquin, The metabolism of Alogliptin can be decreased when combined with Debrisoquine.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N07BB05, nalmefene, Alogliptin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Alogliptin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Alogliptin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Alogliptin can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Alogliptin can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Alogliptin.]
[N06AA01, desipramine, The metabolism of Alogliptin can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Alogliptin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Alogliptin.]
[V04CH02, indigo carmine, Alogliptin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Alogliptin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Alogliptin.]
[G04BD04, oxybutynin, The metabolism of Alogliptin can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Alogliptin can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Alogliptin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Alogliptin can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Alogliptin can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Alogliptin can be decreased when combined with Paroxetine.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V03AH01, diazoxide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Alogliptin.]
[R05DA08, pholcodine, Alogliptin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of angioedema can be increased when Diclofenac is combined with Alogliptin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Alogliptin can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Alogliptin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Alogliptin.]
[C03CA03, piretanide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Piretanide.]
[C08CA03, isradipine, The metabolism of Alogliptin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Alogliptin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Alogliptin.]
[C01AA05, digoxin, Alogliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Alogliptin can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Alogliptin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Alogliptin.]
[C08DB01, diltiazem, The metabolism of Alogliptin can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Alogliptin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The metabolism of Alogliptin can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R06AA02, diphenhydramine, The metabolism of Alogliptin can be decreased when combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Quinapril.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Alogliptin.]
[A03FA02, cisapride, The metabolism of Alogliptin can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of angioedema can be increased when Alogliptin is combined with Ramipril.]
[S01XA23, sirolimus, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Sirolimus.]
[N05AL04, remoxipride, The metabolism of Alogliptin can be decreased when combined with Remoxipride.]
[S01AX06, resorcinol, Alogliptin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Alogliptin.]
[S02AA12, rifamycin SV, The metabolism of Alogliptin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Alogliptin can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, Alogliptin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MB01, rosoxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Alogliptin.]
[A04AD12, aprepitant, The metabolism of Alogliptin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Alogliptin can be decreased when combined with Bortezomib.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Alogliptin can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Alogliptin can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Alogliptin can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Alogliptin.]
[L01DB01, doxorubicin, The metabolism of Alogliptin can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Alogliptin.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Alogliptin can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Alogliptin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Alogliptin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Alogliptin can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Alogliptin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Alogliptin can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Alogliptin.]
[C07AA16, tertatolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Alogliptin.]
[C09AA02, enalapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Alogliptin.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03CA04, torsemide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.]
[C09AA10, trandolapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Trandolapril.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Alogliptin.]
[L02AE04, triptorelin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.]
[J01MA04, enoxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Alogliptin can be decreased when combined with Vinorelbine.]
[S01GX10, epinastine, The metabolism of Alogliptin can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Alogliptin can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Alogliptin.]
[C08CA12, mepirodipine, The metabolism of Alogliptin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of angioedema can be increased when Alogliptin is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Alogliptin can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AX15, zonisamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin glulisine.]
[B01AD03, anistreplase, The risk or severity of angioedema can be increased when Anistreplase is combined with Alogliptin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02CA02, ergotamine, The metabolism of Alogliptin can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Alogliptin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Alogliptin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Alogliptin can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The risk or severity of angioedema can be increased when Conjugated estrogens is combined with Alogliptin.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Alogliptin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Alogliptin.]
[C10AA04, fluvastatin, The metabolism of Alogliptin can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Alogliptin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Alogliptin.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01XA06, ethylmorphine, The metabolism of Alogliptin can be decreased when combined with Ethylmorphine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AE03, sertindole, The metabolism of Alogliptin can be decreased when combined with Sertindole.]
[L04AD02, tacrolimus, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Alogliptin.]
[R06AX12, terfenadine, The metabolism of Alogliptin can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Alogliptin can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Alogliptin can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Alogliptin can be decreased when combined with Encainide.]
[L02AE02, leuprolide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.]
[M01CB01, gold sodium thiomalate, Alogliptin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Alogliptin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Alogliptin can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Alogliptin.]
[N03AX26, fenfluramine, The metabolism of Alogliptin can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Alogliptin.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Alogliptin.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Alogliptin.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Alogliptin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Alogliptin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Alogliptin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Alogliptin.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Alogliptin.]
[N06AB03, fluoxetine, The serum concentration of Alogliptin can be increased when it is combined with Fluoxetine.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Alogliptin.]
[N05AB02, fluphenazine, The metabolism of Alogliptin can be decreased when combined with Fluphenazine.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Alogliptin.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Alogliptin.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L01BC03, tegafur, Alogliptin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Alogliptin.]
[J05AE10, darunavir, The metabolism of Alogliptin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06DA04, galantamine, The metabolism of Alogliptin can be decreased when combined with Galantamine.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Alogliptin.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01XA03, telavancin, Alogliptin may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Alogliptin.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Alogliptin.]
[A10BB01, glyburide, Alogliptin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Alogliptin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Alogliptin may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, The metabolism of Alogliptin can be decreased when combined with Dexmedetomidine.]
[C02CA04, doxazosin, The metabolism of Alogliptin can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Alogliptin.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C07AB09, esmolol, The metabolism of Alogliptin can be decreased when combined with Esmolol.]
[M01CB04, aurothioglucose, Alogliptin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C09AA09, fosinopril, The risk or severity of angioedema can be increased when Alogliptin is combined with Fosinopril.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L02AE03, goserelin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Alogliptin can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Alogliptin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Alogliptin.]
[L02AE05, histrelin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Alogliptin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin aspart.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of angioedema can be increased when Losartan is combined with Alogliptin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Alogliptin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AG01, nevirapine, The metabolism of Alogliptin can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Alogliptin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Alogliptin.]
[C09AA04, perindopril, The risk or severity of angioedema can be increased when Alogliptin is combined with Perindopril.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Alogliptin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Alogliptin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Alogliptin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Alogliptin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G04BD06, propiverine, Alogliptin may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Hydroxychloroquine.]
[B05AA07, hetastarch, Alogliptin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The metabolism of Alogliptin can be decreased when combined with Hydroxyzine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Alogliptin.]
[R02AX02, ibuprofen, The risk or severity of angioedema can be increased when Ibuprofen is combined with Alogliptin.]
[B05XA08, sodium acetate, Alogliptin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Alogliptin can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Alogliptin.]
[N06AA02, imipramine, The metabolism of Alogliptin can be decreased when combined with Imipramine.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Alogliptin.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Alogliptin.]
[A11HA07, inositol, Alogliptin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Alogliptin.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N01BB08, articaine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Alogliptin.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BH02, vildagliptin, The risk or severity of angioedema can be increased when Vildagliptin is combined with Alogliptin.]
[C10AA06, cerivastatin, The metabolism of Alogliptin can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Quinethazone.]
[V03AB01, ipecac, Alogliptin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Alogliptin.]
[N06AF05, iproniazid, The metabolism of Alogliptin can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Alogliptin.]
[C09AA16, imidapril, The risk or severity of angioedema can be increased when Alogliptin is combined with Imidapril.]
[N04BX02, entacapone, The metabolism of Alogliptin can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Alogliptin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Exenatide is combined with Alogliptin.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AX18, reboxetine, The metabolism of Alogliptin can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Alogliptin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Alogliptin.]
[L04AC07, tocilizumab, The metabolism of Alogliptin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AC22, prasugrel, Alogliptin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Alogliptin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Alogliptin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L04AA24, abatacept, The metabolism of Alogliptin can be increased when combined with Abatacept.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Alogliptin is combined with Ketotifen.]
[N04BC09, rotigotine, The metabolism of Alogliptin can be decreased when combined with Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Alogliptin.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Alogliptin can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C07AG01, labetalol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Alogliptin can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Alogliptin.]
[S01AA21, amikacin, Alogliptin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The metabolism of Alogliptin can be decreased when combined with Lisuride.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Alogliptin.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Alogliptin.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Alogliptin can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Temsirolimus.]
[B05XA11, magnesium chloride, Alogliptin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Alogliptin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Alogliptin.]
[L01BA05, pralatrexate, Alogliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Alogliptin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R06AE05, meclizine, The metabolism of Alogliptin can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C03BA05, mefruside, The therapeutic efficacy of Alogliptin can be increased when used in combination with Mefruside.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AB04, mephenytoin, The metabolism of Alogliptin can be decreased when combined with Mephenytoin.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G04BX16, tiopronin, Alogliptin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The metabolism of Alogliptin can be decreased when combined with Mesoridazine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Alogliptin.]
[N05AX13, paliperidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.]
[A04AA04, dolasetron, The metabolism of Alogliptin can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, The metabolism of Alogliptin can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01EC05, methazolamide, The therapeutic efficacy of Alogliptin can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Alogliptin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Alogliptin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Alogliptin.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The metabolism of Alogliptin can be decreased when combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Alogliptin can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V04CG05, methylene blue, The metabolism of Alogliptin can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Alogliptin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Alogliptin.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Alogliptin.]
[A03FA01, metoclopramide, The metabolism of Alogliptin can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The metabolism of Alogliptin can be decreased when combined with Metoprolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Alogliptin can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Alogliptin can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Alogliptin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Alogliptin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of angioedema can be increased when Valsartan is combined with Alogliptin.]
[L01XX23, mitotane, The metabolism of Alogliptin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Alogliptin can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Alogliptin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Alogliptin.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Alogliptin can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Alogliptin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Alogliptin can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Alogliptin.]
[N03AB05, fosphenytoin, The metabolism of Alogliptin can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[V03AB15, naloxone, The metabolism of Alogliptin can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Alogliptin can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Alogliptin.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Troglitazone is combined with Alogliptin.]
[N06AX21, duloxetine, The metabolism of Alogliptin can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S03AA01, neomycin, Alogliptin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Alogliptin.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AX14, iloperidone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[L03AX16, plerixafor, Alogliptin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Alogliptin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Alogliptin.]
[C09CA07, telmisartan, The risk or severity of angioedema can be increased when Telmisartan is combined with Alogliptin.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C10AD02, niacin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Alogliptin.]
[C08CA04, nicardipine, The metabolism of Alogliptin can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Alogliptin can be decreased when combined with Nicergoline.]
[C08CA05, nifedipine, The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Alogliptin.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Alogliptin.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Alogliptin.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Alogliptin.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[G03DC02, norethindrone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Alogliptin.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Alogliptin.]
[H01CB02, octreotide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Alogliptin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Alogliptin can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Alogliptin.]
[N02AA02, opium, Alogliptin may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of angioedema can be increased when Reteplase is combined with Alogliptin.]
[G04CA02, tamsulosin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Alogliptin can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Alogliptin.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Alogliptin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Alogliptin can be decreased when combined with Oxycodone.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Alogliptin.]
[N02AA11, oxymorphone, The metabolism of Alogliptin can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Alogliptin.]
[N05AH05, asenapine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Asenapine.]
[J04AB30, capreomycin, Alogliptin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Alogliptin.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Alogliptin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Alogliptin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Alogliptin.]
[J01CE09, penicillin G procaine, Alogliptin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Alogliptin can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Alogliptin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08EX02, perhexiline, The metabolism of Alogliptin can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Alogliptin can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Alogliptin can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Alogliptin.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Phenformin is combined with Alogliptin.]
[N03AA02, phenobarbital, The metabolism of Alogliptin can be increased when combined with Phenobarbital.]
[A08AA01, phentermine, The therapeutic efficacy of Alogliptin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N03AB02, phenytoin, The metabolism of Alogliptin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Alogliptin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Levofloxacin.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Alogliptin can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Alogliptin.]
[C07AA03, pindolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Alogliptin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Alogliptin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of angioedema can be increased when Eprosartan is combined with Alogliptin.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Alogliptin can be decreased when combined with Delavirdine.]
[S01XA13, alteplase, The risk or severity of angioedema can be increased when Alteplase is combined with Alogliptin.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Alogliptin.]
[L04AC08, canakinumab, The metabolism of Alogliptin can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Alogliptin can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Alogliptin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Practolol.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Alogliptin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Alogliptin.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Alogliptin.]
[P01BA03, primaquine, The metabolism of Alogliptin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Alogliptin can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Alogliptin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Alogliptin.]
[S01HA05, procaine, Procaine may increase the hypoglycemic activities of Alogliptin.]
[L01XB01, procarbazine, Procarbazine may increase the hypoglycemic activities of Alogliptin.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N05AB04, prochlorperazine, The metabolism of Alogliptin can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, The metabolism of Alogliptin can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Alogliptin can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Alogliptin can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N02AC04, propoxyphene, The metabolism of Alogliptin can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Alogliptin can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Alogliptin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, Alogliptin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Alogliptin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[R06AC01, pyrilamine, The metabolism of Alogliptin can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Alogliptin can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Alogliptin can be decreased when combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Alogliptin.]
[A02BA02, ranitidine, The metabolism of Alogliptin can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of angioedema can be increased when Alogliptin is combined with Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Alogliptin can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Alogliptin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Alogliptin.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[N04BD01, selegiline, Selegiline may increase the hypoglycemic activities of Alogliptin.]
[J01GB08, sisomicin, Alogliptin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Alogliptin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Alogliptin.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Alogliptin.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Pioglitazone.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Pioglitazone.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Pioglitazone.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Pioglitazone.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Pioglitazone.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Pioglitazone.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Glymidine.]
[L02BA01, tamoxifen, The metabolism of Pioglitazone can be decreased when combined with Tamoxifen.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Pioglitazone.]
[N05AE05, lurasidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Pioglitazone.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Pioglitazone.]
[B01AC05, ticlopidine, The metabolism of Pioglitazone can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Timolol.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Pioglitazone.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Pioglitazone.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypoglycemic activities of Pioglitazone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Pioglitazone.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Pioglitazone.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Trichlormethiazide.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Pioglitazone.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Pioglitazone.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Pioglitazone.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Pioglitazone.]
[A03AA05, trimebutine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Pioglitazone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Pioglitazone.]
[J01EA01, trimethoprim, The metabolism of Pioglitazone can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Pioglitazone.]
[J01FA08, troleandomycin, The metabolism of Pioglitazone can be decreased when combined with Troleandomycin.]
[L02BX03, abiraterone, The metabolism of Pioglitazone can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Pioglitazone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Pioglitazone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Pioglitazone can be decreased when combined with Rilpivirine.]
[C08DA01, verapamil, The metabolism of Pioglitazone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Pioglitazone can be decreased when combined with Viloxazine.]
[C03BA10, xipamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Pioglitazone.]
[J05AE02, indinavir, The metabolism of Pioglitazone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Pioglitazone can be decreased when combined with Crizotinib.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Pioglitazone.]
[C07AB03, atenolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Pioglitazone can be decreased when combined with Voriconazole.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Pioglitazone.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Pioglitazone.]
[M03BX01, baclofen, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Baclofen.]
[V03AX03, cobicistat, The metabolism of Pioglitazone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Pioglitazone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Pioglitazone can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Pioglitazone can be decreased when combined with Teriflunomide.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Pioglitazone.]
[J05AE04, nelfinavir, The metabolism of Pioglitazone can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Pioglitazone.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Pioglitazone.]
[L01EX07, cabozantinib, The metabolism of Pioglitazone can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pasireotide.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Pioglitazone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Pioglitazone.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Pioglitazone.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bendroflumethiazide.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Pioglitazone can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Pioglitazone.]
[A10AE05, insulin detemir, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Pramlintide.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Pioglitazone.]
[L04AA18, everolimus, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Pioglitazone can be increased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The serum concentration of Pioglitazone can be increased when it is combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Pioglitazone.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Pioglitazone.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Pioglitazone.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Pioglitazone.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Lixisenatide.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Pioglitazone.]
[G03AC08, etonogestrel, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Pioglitazone can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[C07AB04, acebutolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Pioglitazone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Pioglitazone can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Pioglitazone can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Betaxolol.]
[C10AB02, bezafibrate, The metabolism of Pioglitazone can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Pioglitazone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ceritinib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Pioglitazone.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Dulaglutide.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Pioglitazone.]
[L04AC10, secukinumab, The metabolism of Pioglitazone can be increased when combined with Secukinumab.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Brexpiprazole.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Pioglitazone.]
[S01EC01, acetazolamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Pioglitazone.]
[J02AC05, isavuconazole, The metabolism of Pioglitazone can be increased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Pioglitazone.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Pioglitazone.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Pioglitazone.]
[L01XX52, venetoclax, The metabolism of Pioglitazone can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Bromocriptine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Pioglitazone.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Pioglitazone.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Pioglitazone.]
[C03CA02, bumetanide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bumetanide.]
[C07AA19, bupranolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Pioglitazone.]
[L02AE01, buserelin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Buserelin.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Pioglitazone.]
[L01EF02, ribociclib, The metabolism of Pioglitazone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Pioglitazone.]
[N02BF02, pregabalin, The risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Pioglitazone.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Pioglitazone.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Benfluorex.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Pioglitazone.]
[J05AE09, tipranavir, The metabolism of Pioglitazone can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Pioglitazone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Pioglitazone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Pioglitazone.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Pioglitazone.]
[J01MA23, delafloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Delafloxacin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Pioglitazone.]
[L01XH01, vorinostat, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Pioglitazone can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bopindolol.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Pioglitazone.]
[J05AX18, letermovir, The metabolism of Pioglitazone can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Pioglitazone.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Ertugliflozin.]
[L02BB05, apalutamide, The metabolism of Pioglitazone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Pioglitazone can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Pioglitazone can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Pioglitazone can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Pioglitazone.]
[L01XX62, ivosidenib, The metabolism of Pioglitazone can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Pioglitazone can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Pioglitazone can be increased when combined with Tecovirimat.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Pioglitazone.]
[L04AA39, emapalumab, The metabolism of Pioglitazone can be increased when combined with Emapalumab.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Pioglitazone.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Pioglitazone.]
[P02BX04, triclabendazole, The metabolism of Pioglitazone can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The metabolism of Pioglitazone can be decreased when combined with Clarithromycin.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Pioglitazone.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Pioglitazone.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Pioglitazone.]
[C09CA06, candesartan, The metabolism of Pioglitazone can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Pioglitazone can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Pioglitazone.]
[L01EM03, alpelisib, The metabolism of Pioglitazone can be decreased when combined with Alpelisib.]
[N07XX11, pitolisant, The serum concentration of Pioglitazone can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Pioglitazone.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin pork.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Pioglitazone.]
[G03AC09, desogestrel, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Pioglitazone can be decreased when it is combined with Cenobamate.]
[L04AA53, teprotumumab, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Teprotumumab.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Pioglitazone can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Pioglitazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Pioglitazone.]
[G03DB08, dienogest, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Pioglitazone.]
[M01AH02, rofecoxib, The metabolism of Pioglitazone can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Pioglitazone can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Pioglitazone.]
[C01BD07, dronedarone, The metabolism of Pioglitazone can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Pioglitazone.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Pioglitazone.]
[L01EX22, selpercatinib, The serum concentration of Pioglitazone can be increased when it is combined with Selpercatinib.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Pioglitazone.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Pioglitazone.]
[L04AC19, satralizumab, The serum concentration of Pioglitazone can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Pioglitazone.]
[L01EX23, pralsetinib, The metabolism of Pioglitazone can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Pioglitazone.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorthalidone.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Pioglitazone.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Pioglitazone.]
[B06AC06, berotralstat, The metabolism of Pioglitazone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Pioglitazone can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Pioglitazone can be increased when it is combined with Abametapir.]
[J01MB07, flumequine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Pioglitazone.]
[A10AF01, insulin, regular, human, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin human.]
[A02BA01, cimetidine, The metabolism of Pioglitazone can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Pioglitazone.]
[J01MB06, cinoxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Pioglitazone can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Pioglitazone.]
[H01AC07, somapacitan, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Pioglitazone.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lonapegsomatropin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Pioglitazone.]
[N06AX25, St. John's wort extract, The metabolism of Pioglitazone can be increased when combined with St. John's Wort.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Pioglitazone.]
[B06AX04, mitapivat, The metabolism of Pioglitazone can be increased when combined with Mitapivat.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Pioglitazone.]
[C01EB24, mavacamten, The serum concentration of Pioglitazone can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Clopamide.]
[H01CC04, linzagolix, The serum concentration of Pioglitazone can be increased when it is combined with Linzagolix.]
[N05AH02, clozapine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Pioglitazone.]
[H01AC08, somatrogon, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Pioglitazone can be increased when combined with Bimekizumab.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Pioglitazone.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Pioglitazone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Pioglitazone.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Pioglitazone.]
[J02AC02, itraconazole, The metabolism of Pioglitazone can be decreased when combined with Itraconazole.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Pioglitazone.]
[J02AC04, posaconazole, The metabolism of Pioglitazone can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Pioglitazone.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Pioglitazone.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Pioglitazone can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Pioglitazone.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Pioglitazone.]
[C07AA14, mepindolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Pioglitazone.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Pioglitazone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Pioglitazone.]
[L01AA01, cyclophosphamide, The metabolism of Pioglitazone can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Pioglitazone.]
[S01XA18, cyclosporine, The metabolism of Pioglitazone can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Pioglitazone.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Pioglitazone can be decreased when combined with Conivaptan.]
[G03XA01, danazol, The metabolism of Pioglitazone can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Pioglitazone.]
[C07AB12, nebivolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Pioglitazone can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Pioglitazone can be decreased when combined with Nilutamide.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Pioglitazone.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Pioglitazone.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Pioglitazone.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Pioglitazone.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Pioglitazone.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Pioglitazone.]
[S03BA01, dexamethasone, The metabolism of Pioglitazone can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Pioglitazone can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Pioglitazone can be increased when combined with Adalimumab.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Pioglitazone.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Pioglitazone.]
[B01AC04, clopidogrel, The serum concentration of Pioglitazone can be increased when it is combined with Clopidogrel.]
[V03AH01, diazoxide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Pioglitazone.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Pioglitazone.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Phthalylsulfathiazole.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Pioglitazone.]
[S01AA13, fusidic acid, The metabolism of Pioglitazone can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Pioglitazone.]
[L01EB02, erlotinib, The serum concentration of Pioglitazone can be increased when it is combined with Erlotinib.]
[C03CA03, piretanide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Pioglitazone.]
[C08CA03, isradipine, The metabolism of Pioglitazone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Pioglitazone.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Pioglitazone.]
[J05AE08, atazanavir, The metabolism of Pioglitazone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Pioglitazone.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Pioglitazone.]
[C08DB01, diltiazem, The metabolism of Pioglitazone can be decreased when combined with Diltiazem.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Pioglitazone.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Pioglitazone.]
[S01XA23, sirolimus, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Sirolimus.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Pioglitazone.]
[S02AA12, rifamycin SV, The metabolism of Pioglitazone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Pioglitazone can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Pioglitazone can be increased when combined with Rifaximin.]
[N05AX08, risperidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.]
[J01MB01, rosoxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Pioglitazone can be decreased when combined with Aprepitant.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Fosamprenavir.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Pioglitazone.]
[R03AC12, salmeterol, The serum concentration of Pioglitazone can be increased when it is combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Pioglitazone.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Pioglitazone.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Pioglitazone.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Pioglitazone.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Pioglitazone.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Pioglitazone.]
[J01MA05, temafloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Pioglitazone.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Pioglitazone.]
[C07AA16, tertatolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Pioglitazone.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Pioglitazone.]
[N03AX11, topiramate, The serum concentration of Pioglitazone can be decreased when it is combined with Topiramate.]
[C03CA04, torsemide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Torasemide.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Pioglitazone.]
[L02AE04, triptorelin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin.]
[J01MA04, enoxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Enoxacin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Pioglitazone.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Pioglitazone.]
[C08CA12, mepirodipine, The metabolism of Pioglitazone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Epinephrine.]
[N03AX15, zonisamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Pioglitazone.]
[N02CA02, ergotamine, The metabolism of Pioglitazone can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Pioglitazone can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Estradiol.]
[R03BA09, fluticasone furoate, The serum concentration of Pioglitazone can be increased when it is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The serum concentration of Pioglitazone can be increased when it is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Pioglitazone can be decreased when combined with Fluvastatin.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Pioglitazone.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethinylestradiol.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Pioglitazone.]
[L04AD02, tacrolimus, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Fleroxacin.]
[R06AX12, terfenadine, The metabolism of Pioglitazone can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Pioglitazone.]
[L02AE02, leuprolide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.]
[C08CA02, felodipine, The serum concentration of Pioglitazone can be increased when it is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Pioglitazone.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Pioglitazone.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Pioglitazone.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Pioglitazone.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Pioglitazone.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Pioglitazone.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Pioglitazone.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Pioglitazone.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Pioglitazone.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Pioglitazone.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Pioglitazone.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Pioglitazone.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Pioglitazone.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Pioglitazone.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Pioglitazone.]
[J05AE10, darunavir, The metabolism of Pioglitazone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Pioglitazone.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Pioglitazone.]
[C10AB04, gemfibrozil, The serum concentration of Pioglitazone can be increased when it is combined with Gemfibrozil.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Pioglitazone.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Pioglitazone.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Pioglitazone.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Pioglitazone.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Pioglitazone.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Pioglitazone.]
[L01EX02, sorafenib, The serum concentration of Pioglitazone can be increased when it is combined with Sorafenib.]
[L02AE03, goserelin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Pioglitazone.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Pioglitazone.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Pioglitazone.]
[L02AE05, histrelin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin aspart.]
[C09CA01, losartan, The metabolism of Pioglitazone can be decreased when combined with Losartan.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Pioglitazone.]
[C08CA10, nilvadipine, The metabolism of Pioglitazone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Pioglitazone.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The metabolism of Pioglitazone can be increased when combined with Hydrocortisone.]
[D07AC16, hydrocortisone aceponate, The metabolism of Pioglitazone can be increased when combined with Hydrocortisone aceponate.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydroflumethiazide.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Hydroxychloroquine.]
[J04AB04, rifabutin, The metabolism of Pioglitazone can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Pioglitazone.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Pioglitazone.]
[L01AA06, ifosfamide, The metabolism of Pioglitazone can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Pioglitazone.]
[N06AA02, imipramine, Imipramine may decrease the hypoglycemic activities of Pioglitazone.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Pioglitazone.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Pioglitazone.]
[C03BA11, indapamide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Pioglitazone.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Pioglitazone.]
[N01BB08, articaine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Sitagliptin.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Pioglitazone.]
[C07AA01, alprenolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quinethazone.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Pioglitazone.]
[N06AF05, iproniazid, Iproniazid may increase the hypoglycemic activities of Pioglitazone.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Pioglitazone.]
[J04AC01, isoniazid, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Exenatide.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Pioglitazone.]
[L04AC07, tocilizumab, The metabolism of Pioglitazone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Pioglitazone.]
[J02AB02, ketoconazole, The metabolism of Pioglitazone can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Pioglitazone can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Pioglitazone can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Pioglitazone can be increased when combined with Abatacept.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Pioglitazone is combined with Ketotifen.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Labetalol.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Levonorgestrel.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Pioglitazone.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Pioglitazone.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Pioglitazone.]
[C10AA02, lovastatin, The metabolism of Pioglitazone can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Pioglitazone.]
[L01EA03, nilotinib, The metabolism of Pioglitazone can be decreased when combined with Nilotinib.]
[C03BA05, mefruside, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Mefruside.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Pioglitazone.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Pioglitazone.]
[N05AX13, paliperidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.]
[H01CB03, lanreotide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide.]
[S01EC05, methazolamide, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Pioglitazone can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Pioglitazone.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The metabolism of Pioglitazone can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Pioglitazone.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Pioglitazone.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Pioglitazone.]
[C03BA08, metolazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Pioglitazone can be decreased when combined with Metronidazole.]
[S02AA13, miconazole, The metabolism of Pioglitazone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Pioglitazone.]
[G03XB01, mifepristone, The serum concentration of Pioglitazone can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Pioglitazone can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Pioglitazone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Pioglitazone.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Pioglitazone.]
[L04AB05, certolizumab pegol, The metabolism of Pioglitazone can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Pioglitazone.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Pioglitazone.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Pioglitazone.]
[G03XC01, raloxifene, The metabolism of Pioglitazone can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Pioglitazone.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Pioglitazone.]
[C07AA12, nadolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Nadolol.]
[V03AB15, naloxone, The metabolism of Pioglitazone can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Pioglitazone can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Pioglitazone.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Pioglitazone.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Pioglitazone.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Pioglitazone.]
[N05AX14, iloperidone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Pioglitazone.]
[C10AD02, niacin, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Pioglitazone.]
[C08CA04, nicardipine, The metabolism of Pioglitazone can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be decreased when it is combined with Pioglitazone.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Pioglitazone.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Pioglitazone.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Pioglitazone.]
[G03DC02, norethindrone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Pioglitazone.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Pioglitazone.]
[H01CB02, octreotide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Pioglitazone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Pioglitazone.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Pioglitazone.]
[G04CA02, tamsulosin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Tamsulosin.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Pioglitazone.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Oxprenolol.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Pioglitazone.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Pioglitazone.]
[N05AH05, asenapine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Asenapine.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Pioglitazone.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Pioglitazone.]
[J01MA03, pefloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Pefloxacin.]
[C07AA23, penbutolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Pioglitazone.]
[N05CA01, pentobarbital, The metabolism of Pioglitazone can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Pioglitazone.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Pioglitazone.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Pioglitazone can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Pioglitazone.]
[A08AA01, phentermine, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Phentermine.]
[N03AB02, phenytoin, The metabolism of Pioglitazone can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Pioglitazone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Pioglitazone.]
[C07AA03, pindolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Pioglitazone.]
[J05AE01, saquinavir, The metabolism of Pioglitazone can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pipotiazine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Pioglitazone.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Pioglitazone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Pioglitazone can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Pioglitazone.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Pioglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Pioglitazone.]
[L04AC08, canakinumab, The metabolism of Pioglitazone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Pioglitazone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Pioglitazone.]
[C07AB01, practolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Practolol.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Pioglitazone.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Pioglitazone.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Pioglitazone.]
[P01BA03, primaquine, The metabolism of Pioglitazone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Pioglitazone can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Pioglitazone can be increased when combined with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypoglycemic activities of Pioglitazone.]
[L01XB01, procarbazine, Procarbazine may increase the hypoglycemic activities of Pioglitazone.]
[C10AB05, fenofibrate, The metabolism of Pioglitazone can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Progesterone.]
[C01BC03, propafenone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Propafenone.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Pioglitazone.]
[C07AA05, propranolol, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Propranolol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Pioglitazone.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Pioglitazone.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Aripiprazole.]
[P01BD01, pyrimethamine, The metabolism of Pioglitazone can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Pioglitazone can be increased when combined with Quinidine.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Pioglitazone.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Pioglitazone.]
[J04AB02, rifampin, The metabolism of Pioglitazone can be increased when combined with Rifampicin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Pioglitazone.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Pioglitazone.]
[N05CA06, secobarbital, The metabolism of Pioglitazone can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Pioglitazone.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Pioglitazone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Pioglitazone.]
[C03DA01, spironolactone, The metabolism of Pioglitazone can be decreased when combined with Spironolactone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Pioglitazone can be increased when combined with Hydrocortisone butyrate.]
[D07AB11, hydrocortisone probutate, The metabolism of Pioglitazone can be increased when combined with Hydrocortisone probutate.]
[H02CA04, levoketoconazole, The metabolism of Pioglitazone can be decreased when combined with Levoketoconazole.]
